-
-
-
-
-
-
-
Madrigal Pharma (MDGL) Misses Q4 EPS by 197c
-
-
-
-
-
-
-
Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025
-
-
-
-
-
-
-
Madrigal Pharma (MDGL) Tops Q1 EPS by 54c
-
-
-
-
-
-
-
Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH
-
-
-
-
-
-
-
Madrigal Pharma (MDGL) Tops Q2 EPS by 38c
-
-
-
-
-
-
-
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
-
-
-
-
-
-
-
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
-
1,206,237 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

